Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2015, Article ID 540154, 10 pages
http://dx.doi.org/10.1155/2015/540154
Review Article

Morphine for the Treatment of Pain in Sickle Cell Disease

1Stanford University School of Medicine, Stanford, CA 94305, USA
2Vascular Biology Center, Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota Medical School, Mayo Mail Code 480, 420 Delaware Street SE, Minneapolis, MN 55455, USA
3Christiana Care Health System, Department of Internal Medicine & Pediatrics, Newark, DE 19713, USA
4Cardeza Foundation for Hematologic Research, Jefferson Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA

Received 20 August 2014; Accepted 18 November 2014

Academic Editor: Philippe Connes

Copyright © 2015 Mihir Gupta et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. B. Piel, S. I. Hay, S. Gupta, D. J. Weatherall, and T. N. Williams, “Global burden of sickle cell anaemia in children under five, 2010–2050: modelling based on demographics, excess mortality, and interventions,” PLoS Medicine, vol. 10, no. 7, Article ID e1001484, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. S. K. Ballas, K. Gupta, and P. Adams-Graves, “Sickle cell pain: a critical reappraisal,” Blood, vol. 120, no. 18, pp. 3647–3656, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. D. Fletcher and V. Martinez, “Opioid-induced hyperalgesia in patients after surgery: a systematic review and a meta-analysis,” British Journal of Anaesthesia, vol. 112, no. 6, pp. 991–1004, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. S. H. Kim, N. Stoicea, S. Soghomonyan, and S. D. Bergese, “Intraoperative use of remifentanil and opioid induced hyperalgesia/acute opioid tolerance: systematic review,” Frontiers in Pharmacology, vol. 5, article 108, 2014. View at Google Scholar
  5. D. G. Soergel, R. A. Subach, N. Burnham et al., “Biased agonism of the μ-opioid receptor by TRV130 increases analgesia and reduces on-target adverse effects versus morphine: a randomized, double-blind, placebo-controlled, crossover study in healthy volunteers,” Pain, vol. 155, no. 9, pp. 1829–1835, 2014. View at Publisher · View at Google Scholar · View at PubMed
  6. K. Gupta, S. Kshirsagar, L. Chang et al., “Morphine stimulates angiogenesis by activating proangiogenic and survival-promoting signaling and promotes breast tumor growth,” Cancer Research, vol. 62, no. 15, pp. 4491–4498, 2002. View at Google Scholar · View at Scopus
  7. I. D. Buchanan, M. Woodward, and G. W. Reed, “Opioid selection during sickle cell pain crisis and its impact on the development of acute chest syndrome,” Pediatric Blood & Cancer, vol. 45, no. 5, pp. 716–724, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. L. Spikes, P. Dalvi, O. Tawfik et al., “Enhanced pulmonary arteriopathy in simian immunodeficiency virus-infected macaques exposed to morphine,” The American Journal of Respiratory and Critical Care Medicine, vol. 185, no. 11, pp. 1235–1243, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. L. Weber, M. Farooqui, J. Nguyen et al., “Morphine induces mesangial cell proliferation and glomerulopathy via κ-opioid receptors,” American Journal of Physiology: Renal Physiology, vol. 294, no. 6, pp. F1388–F1397, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. X. Lan, P. Rai, N. Chandel et al., “Morphine induces albuminuria by compromising podocyte integrity,” PLoS ONE, vol. 8, no. 3, Article ID e55748, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  11. D. Zylla, B. L. Gourley, D. Vang et al., “Opioid requirement, opioid receptor expression, and clinical outcomes in patients with advanced prostate cancer,” Cancer, vol. 119, no. 23, pp. 4103–4110, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  12. D. Zylla, M. A. Kuskowski, K. Gupta, and P. Gupta, “Association of opioid requirement and cancer pain with survival in advanced non-small cell lung cancer,” British Journal of Anaesthesia. In press.
  13. E. E. Cunningham, M. A. Zielezny, and R. C. Venuto, “Heroin-associated nephropathy. A nationwide problem,” Journal of the American Medical Association, vol. 250, no. 21, pp. 2935–2936, 1983. View at Publisher · View at Google Scholar · View at Scopus
  14. D. C. Rees, T. N. Williams, and M. T. Gladwin, “Sickle-cell disease,” The Lancet, vol. 376, no. 9757, pp. 2018–2031, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. O. S. Platt, D. J. Brambilla, W. F. Rosse et al., “Mortality in sickle cell disease. Life expectancy and risk factors for early death,” The New England Journal of Medicine, vol. 330, no. 23, pp. 1639–1644, 1994. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  16. C. D. Dampier, W. R. Smith, C. G. Wager et al., “IMPROVE trial: a randomized controlled trial of patient-controlled analgesia for sickle cell painful episodes: rationale, design challenges, initial experience, and recommendations for future studies,” Clinical Trials, vol. 10, no. 2, pp. 319–331, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  17. “Evidence based management of sickle cell disease,” Expert Panel Report, 2014, http://www.nhlbi.nih.gov/health-pro/guidelines/sickle-cell-disease-guidelines.
  18. S. K. Ballas, Sickle Cell Pain, IASP Press, Washington, DC, USA, 2014.
  19. D. S. Darbari, M. Neely, J. van den Anker, and S. Rana, “Increased clearance of morphine in sickle cell disease: implications for pain management,” Journal of Pain, vol. 12, no. 5, pp. 531–538, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. C. D. Dampier, B. N. Y. Setty, J. Logan, J. G. Ioli, and R. Dean, “Intravenous morphine pharmacokinetics in pediatric patients with sickle cell disease,” Journal of Pediatrics, vol. 126, no. 3, pp. 461–647, 1995. View at Publisher · View at Google Scholar · View at Scopus
  21. D. R. Kohli, Y. Li, S. G. Khasabov et al., “Pain-related behaviors and neurochemical alterations in mice expressing sickle hemoglobin: modulation by cannabinoids,” Blood, vol. 116, no. 3, pp. 456–465, 2010. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. C. A. Hillery, P. C. Kerstein, D. Vilceanu et al., “Transient receptor potential vanilloid 1 mediates pain in mice with severe sickle cell disease,” Blood, vol. 118, no. 12, pp. 3376–3383, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. D. M. Cain, D. Vang, D. A. Simone, R. P. Hebbel, and K. Gupta, “Mouse models for studying pain in sickle disease: effects of strain, age, and acuteness,” British Journal of Haematology, vol. 156, no. 4, pp. 535–544, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  24. L. Vincent, D. Vang, J. Nguyen et al., “Mast cell activation contributes to sickle cell pathobiology and pain in mice.,” Blood, vol. 122, no. 11, pp. 1853–1862, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. Close and R. Lottenberg, “Effectiveness of imatinib therapy for a patient with sickle cell anemia and chronic myelocytic leukemia,” in Proceedings of the 51st ASH Annual Meeting and Exposition, New Orleans, La, USA, 2009.
  26. K. Stankovic Stojanovic, B. Thiolière, E. Garandeau, I. Lecomte, C. Bachmeyer, and F. Lionnet, “Chronic myeloid leukaemia and sickle cell disease: could imatinib prevent vaso-occlusive crisis?” British Journal of Haematology, vol. 155, no. 2, pp. 271–272, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. O. J. Biedrzycki, D. Bevan, and S. Lucas, “Fatal overdose due to prescription fentanyl patches in a patient with sickle cell/β-thalassemia and acute chest syndrome: a case report and review of the literature,” The American Journal of Forensic Medicine and Pathology, vol. 30, no. 2, pp. 188–190, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. U. Boerner, S. Abbott, and R. L. Roe, “The metabolism of morphine and heroin in man,” Drug Metabolism Reviews, vol. 4, no. 1, pp. 39–73, 1975. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. S. Y. Yeh, “Urinary excretion of morphine and its metabolites in morphine dependent subjects,” Journal of Pharmacology and Experimental Therapeutics, vol. 192, no. 1, pp. 201–210, 1975. View at Google Scholar · View at Scopus
  30. F. Stain-Texier, P. Sandouk, and J.-M. Scherrmann, “Intestinal absorption and stability of morphine 6-glucuronide in different physiological compartments of the rat,” Drug Metabolism and Disposition, vol. 26, no. 5, pp. 383–387, 1998. View at Google Scholar · View at Scopus
  31. A. Bodenham, K. Quinn, and G. R. Park, “Extrahepatic morphine metabolism in man during the anhepatic phase of orthotopic liver transplantation,” British Journal of Anaesthesia, vol. 63, no. 4, pp. 380–384, 1989. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Waldhoer, S. E. Bartlett, and J. L. Whistler, “Opioid receptors,” Annual Review of Biochemistry, vol. 73, pp. 953–990, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  33. J. L. Whistler, H.-H. Chuang, P. Chu, L. Y. Jan, and M. Von Zastrow, “Functional dissociation of μ opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction,” Neuron, vol. 23, no. 4, pp. 737–746, 1999. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Sternini, M. Spann, B. Anton et al., “Agonist-selective endocytosis of μ opioid receptor by neurons in vivo,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 17, pp. 9241–9246, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. L. He, J. Fong, M. von Zastrow, and J. L. Whistler, “Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization,” Cell, vol. 108, no. 2, pp. 271–282, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. K. Gupta and E. Stephenson, The Endothelium: A Comprehensive Reference, Cambridge University Press, New York, NY, USA, 2007.
  37. H. Wen, Y. Lu, H. Yao, and S. Buch, “Morphine induces expression of platelet-derived growth factor in human brain microvascular endothelial cells: implication for vascular permeability,” PLoS ONE, vol. 6, no. 6, Article ID e21707, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  38. K. Luk, S. Boatman, K. N. Johnson et al., “Influence of morphine on pericyte-endothelial interaction: implications for antiangiogenic therapy,” Journal of Oncology, vol. 2012, Article ID 458385, 10 pages, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  39. P. A. Singleton, L. Moreno-Vinasco, S. Sammani, S. L. Wanderling, J. Moss, and J. G. N. Garcia, “Attenuation of vascular permeability by methylnaltrexone: role of mOP-R and S1P3 transactivation,” The American Journal of Respiratory Cell and Molecular Biology, vol. 37, no. 2, pp. 222–231, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  40. P. A. Singleton, M. W. Lingen, M. J. Fekete, J. G. N. Garcia, and J. Moss, “Methylnaltrexone inhibits opiate and VEGF-induced angiogenesis: role of receptor transactivation,” Microvascular Research, vol. 72, no. 1-2, pp. 3–11, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. C. Chen, M. Farooqui, and K. Gupta, “Morphine stimulates vascular endothelial growth factor-like signaling in mouse retinal endothelial cells,” Current Neurovascular Research, vol. 3, no. 3, pp. 171–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  42. M. Farooqui, Y. Li, T. Rogers et al., “COX-2 inhibitor celecoxib prevents chronic morphine-induced promotion of angiogenesis, tumour growth, metastasis and mortality, without compromising analgesia,” British Journal of Cancer, vol. 97, no. 11, pp. 1523–1531, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  43. E. S. Hatzipantelis, Z. D. Pana, N. Gombakis et al., “Endothelial activation and inflammation biomarkers in children and adolescents with sickle cell disease,” International Journal of Hematology, vol. 98, no. 2, pp. 158–163, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. H. Hyacinth, B. Gee, T. Adamkiewicz et al., “Plasma BDNF and PDGF-AA levels are associated with high TCD velocity and stroke in children with sickle cell anemia,” Cytokine, vol. 60, pp. 302–308, 2012. View at Google Scholar
  45. X. Niu, M. Nouraie, A. Campbell et al., “Angiogenic and inflammatory markers of cardiopulmonary changes in children and adolescents with sickle cell disease,” PLoS ONE, vol. 4, no. 11, Article ID e7956, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. X. Wang, L. C. Loram, K. Ramos et al., “Morphine activates neuroinflammation in a manner parallel to endotoxin,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 16, pp. 6325–6330, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. M. R. Hutchinson, Y. Shavit, P. M. Grace, K. C. Rice, S. F. Maier, and L. R. Watkins, “Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia,” Pharmacological Reviews, vol. 63, no. 3, pp. 772–810, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. J. D. Belcher, C. Chen, J. Nguyen et al., “Heme triggers TLR4 signaling leading to endothelial cell activation and vaso-occlusion in murine sickle cell disease,” Blood, vol. 123, no. 3, pp. 377–390, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  49. S. Ghosh, O. A. Adisa, P. Chappa et al., “Extracellular hemin crisis triggers acute chest syndrome in sickle mice,” Journal of Clinical Investigation, vol. 123, no. 11, pp. 4809–4820, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  50. L. A. Michaels, K. Ohene-Frempong, H. Zhao, and S. D. Douglas, “Serum levels of substance P are elevated in patients with sickle cell disease and increase further during vaso-occlusive crisis,” Blood, vol. 92, no. 9, pp. 3148–3151, 1998. View at Google Scholar · View at Scopus
  51. A. C. Mcclellan, J. C. Luthi, J. R. Lynch et al., “High one year mortality in adults with sickle cell disease and end-stage renal disease,” British Journal of Haematology, vol. 159, no. 3, pp. 360–367, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  52. J. I. Scheinman, “Sickle cell disease and the kidney,” Nature Clinical Practice Nephrology, vol. 5, no. 2, pp. 78–88, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  53. G. B. Da Silva Junior, A. B. Libório, and E. De Francesco Daher, “New insights on pathophysiology, clinical manifestations, diagnosis, and treatment of sickle cell nephropathy,” Annals of Hematology, vol. 90, no. 12, pp. 1371–1379, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. R. Arerangaiah, N. Chalasani, A. Udager et al., “Opioids induce renal abnormalities in tumor-bearing mice,” Nephron Experimental Nephrology, vol. 105, no. 3, pp. e80–e89, 2007. View at Google Scholar
  55. M. L. Weber, C. Chen, Y. Li et al., “Morphine stimulates platelet-derived growth factor receptor-β signalling in mesangial cells in vitro and transgenic sickle mouse kidney in vivo,” British Journal of Anaesthesia, vol. 111, no. 6, pp. 1004–1012, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  56. S. Atici, I. Cinel, L. Cinel, N. Doruk, G. Eskandari, and U. Oral, “Liver and kidney toxicity in chronic use of opioids: an experimental long term treatment model,” Journal of Biosciences, vol. 30, no. 2, pp. 245–252, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. J. F. Borzelleca, J. L. Egle Jr., L. S. Harris, D. N. Johnson, J. B. Terrill, and J. A. Nuite Belleville, “Toxicological evaluation of μ-agonists part I: assessment of toxicity following 30 days of repeated oral dosing of male and female rats with levo-alpha-acetylmethadol HCl (LAAM),” Journal of Applied Toxicology, vol. 14, no. 6, pp. 435–446, 1994. View at Publisher · View at Google Scholar · View at Scopus
  58. P. C. Singhal, M. Pamarthi, R. Shah, D. Chandra, and N. Gibbons, “Morphine stimulates superoxide formation by glomerular mesangial cells,” Inflammation, vol. 18, no. 3, pp. 293–299, 1994. View at Publisher · View at Google Scholar · View at Scopus
  59. B. M. Sharp, W. F. Keane, H. J. Suh, G. Gekker, D. Tsukayama, and P. K. Peterson, “Opioid peptides rapidly stimulate superoxide production by human polymorphonuclear leukocytes and macrophages,” Endocrinology, vol. 117, no. 2, pp. 793–795, 1985. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. M. L. Weber, D. Vang, P. E. Velho et al., “Morphine promotes renal pathology in sickle mice,” International Journal of Nephrology and Renovascular Disease, vol. 5, pp. 109–118, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  61. P. C. Singhal, C. Q. Pan, S. Sagar, N. Gibbons, and E. Valderrama, “Morphine enhances deposition of ferritin-antiferritin complexes in the glomerular mesangium,” Nephron, vol. 70, no. 2, pp. 229–234, 1995. View at Publisher · View at Google Scholar · View at Scopus
  62. A. A. Kapasi, N. Gibbons, J. Mattana, and P. C. Singhal, “Morphine stimulates mesangial cell TNF-α and nitrite production,” Inflammation, vol. 24, no. 5, pp. 463–476, 2000. View at Publisher · View at Google Scholar · View at Scopus
  63. M. M. Kilcoyne, D. J. Gocke, J. I. Meltzer et al., “Nephrotic syndrome in heroin addicts,” The Lancet, vol. 1, no. 7740, pp. 17–20, 1972. View at Google Scholar · View at Scopus
  64. L. Benjamin, “Sickle cell disease,” in Advances in Pain Research and Therapy, M. B. Max, R. K. Portenoy, and E. M. Laska, Eds., pp. 317–331, Raven Press, New York, NY, USA, 1991. View at Google Scholar
  65. C. Birken, A. Khambalia, A. Dupuis et al., “Morphine is associated with acute chest syndrome in children hospitalized with sickle cell disease,” Hospital Pediatrics, vol. 3, no. 2, pp. 149–155, 2013. View at Publisher · View at Google Scholar
  66. S. K. Ballas and C. H. Park, “Severe hypoxemia secondary to acute sternal infarction in sickle cell anemia,” Journal of Nuclear Medicine, vol. 32, no. 8, pp. 1617–1618, 1991. View at Google Scholar · View at Scopus
  67. P. S. Bellet, K. A. Kalinyak, R. Shukla, M. J. Gelfand, and D. L. Rucknagel, “Incentive spirometry to prevent acute pulmonary complications in sickle cell diseases,” The New England Journal of Medicine, vol. 333, no. 11, pp. 699–703, 1995. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  68. D. L. Rucknagel, K. A. Kalinyak, and M. J. Gelfand, “Rib infarcts and acute chest syndrome in sickle cell diseases,” The Lancet, vol. 337, no. 8745, pp. 831–833, 1991. View at Publisher · View at Google Scholar · View at Scopus
  69. E. P. Vichinsky, L. D. Neumayr, A. N. Earles et al., “Causes and outcomes of the acute chest syndrome in sickle cell disease,” The New England Journal of Medicine, vol. 342, no. 25, pp. 1855–1865, 2000. View at Publisher · View at Google Scholar · View at Scopus
  70. L. A. Styles, C. G. Schalkwijk, A. J. Aarsman, E. P. Vichinsky, B. H. Lubin, and F. A. Kuypers, “Phospholipase A2 levels in acute chest syndrome of sickle cell disease,” Blood, vol. 87, no. 6, pp. 2573–2578, 1996. View at Google Scholar · View at Scopus
  71. M. T. Ashcroft and G. R. Serjeant, “Growth, morbidity, and mortality in a cohort of Jamaican adolescents with homozygous sicke cell disease,” West Indian Medical Journal, vol. 30, no. 4, pp. 197–201, 1981. View at Google Scholar · View at Scopus
  72. R. H. Sprinkle, T. Cole, S. Smith, and G. R. Buchanan, “Acute chest syndrome in children with sickle cell disease. A retrospective analysis of 100 hospitalized cases,” American Journal of Pediatric Hematology/Oncology, vol. 8, no. 2, pp. 105–110, 1986. View at Google Scholar · View at Scopus
  73. E. P. Vichinsky and B. H. Lubin, “Sickle cell anemia and related hemoglobinopathies,” Pediatric Clinics of North America, vol. 27, no. 2, pp. 429–447, 1980. View at Google Scholar · View at Scopus
  74. E. A. Kopecky, S. Jacobson, P. Joshi, and G. Koren, “Systemic exposure to morphine and the risk of acute chest syndrome in sickle cell disease,” Clinical Pharmacology and Therapeutics, vol. 75, no. 3, pp. 140–146, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  75. K. Lewing, K. Britton, M. Debaun, and G. Woods, “The impact of parenteral narcotic choice in the development of acute chest syndrome in sickle cell disease,” Journal of Pediatric Hematology/Oncology, vol. 33, no. 4, pp. 255–260, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. A. A. Kassim and M. R. DeBaun, “Sickle cell disease, vasculopathy, and therapeutics,” Annual Review of Medicine, vol. 64, pp. 451–466, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  77. G. J. Kato, M. T. Gladwin, and M. H. Steinberg, “Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes,” Blood Reviews, vol. 21, no. 1, pp. 37–47, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. F. Parent, D. Bachir, J. Inamo et al., “A hemodynamic study of pulmonary hypertension in sickle cell disease,” The New England Journal of Medicine, vol. 365, no. 1, pp. 44–53, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. N. Dham, G. Ensing, C. Minniti et al., “Prospective echocardiography assessment of pulmonary hypertension and its potential etiologies in children with sickle cell disease,” The American Journal of Cardiology, vol. 104, no. 5, pp. 713–720, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. D. Farmakis and A. Aessopos, “Pulmonary hypertension associated with hemoglobinopathies: prevalent but overlooked,” Circulation, vol. 123, no. 11, pp. 1227–1232, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. M. T. Gladwin and E. Vichinsky, “Pulmonary complications of sickle cell disease,” The New England Journal of Medicine, vol. 359, no. 21, pp. 2194–2265, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  82. J. Nguyen, K. Luk, D. Vang et al., “Morphine stimulates cancer progression and mast cell activation and impairs survival in transgenic mice with breast cancer,” British Journal of Anaesthesia, vol. 113, pp. i4–i13, 2014. View at Publisher · View at Google Scholar · View at PubMed
  83. S. Farha, J. Sharp, K. Asosingh et al., “Mast cell number, phenotype, and function in human pulmonary arterial hypertension,” Pulmonary Circulation, vol. 2, pp. 220–228, 2012. View at Google Scholar
  84. C. W.-S. Lee, C.-H. Muo, J.-A. Liang, F.-C. Sung, and C.-H. Kao, “Association of intensive morphine treatment and increased stroke incidence in prostate cancer patients: a population-based nested case-control study,” Japanese Journal of Clinical Oncology, vol. 43, no. 8, pp. 776–781, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  85. J. Koch, R. Manworren, L. Clark, C. T. Quinn, G. R. Buchanan, and Z. R. Rogers, “Pilot study of continuous co-infusion of morphine and naloxone in children with sickle cell pain crisis,” American Journal of Hematology, vol. 83, no. 9, pp. 728–731, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  86. P. Mucci-LoRusso, B. S. Berman, P. T. Silberstein et al., “Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study,” European Journal of Pain, vol. 2, no. 3, pp. 239–249, 1998. View at Publisher · View at Google Scholar · View at Scopus
  87. P. Klepstad, P. C. Borchgrevink, and S. Kaasa, “Effects on cancer patients’ health-related quality of life after the start of morphine therapy,” Journal of Pain and Symptom Management, vol. 20, no. 1, pp. 19–26, 2000. View at Publisher · View at Google Scholar · View at Scopus
  88. S. J. Panchal, P. Müller-Schwefe, and J. I. Wurzelmann, “Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden,” International Journal of Clinical Practice, vol. 61, no. 7, pp. 1181–1187, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  89. R. K. Portenoy, J. Thomas, M. L. Moehl Boatwright et al., “Subcutaneous methylnaltrexone for the treatment of opioid-induced constipation in patients with advanced illness: a double-blind, randomized, parallel group, dose-ranging study,” Journal of Pain and Symptom Management, vol. 35, no. 5, pp. 458–468, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  90. L. T. Pizz, R. Toner, K. Foley et al., “Relationship between potential opioid-related adverse effects and hospital length of stay in patients receiving opioids after orthopedic surgery,” Pharmacotherapy, vol. 32, no. 6, pp. 502–514, 2012. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. J. Y. Wong, B. Carvalho, and E. T. Riley, “Intrathecal morphine 100 and 200 μg for post-cesarean delivery analgesia: a trade-off between analgesic efficacy and side effects,” International Journal of Obstetric Anesthesia, vol. 22, no. 1, pp. 36–41, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  92. X. Nie, Z.-Y. Wen, Z.-Y. Yan, L. Huang, D. Sun, and B. Cheng, “Effects of morphine on rheological properties of rat red blood cells,” Clinical Hemorheology and Microcirculation, vol. 22, no. 3, pp. 189–195, 2000. View at Google Scholar · View at Scopus
  93. A. Schein, C. Enriquez, T. D. Coates, and J. C. Wood, “Magnetic resonance detection of kidney iron deposition in sickle cell disease: a marker of chronic hemolysis,” Journal of Magnetic Resonance Imaging, vol. 28, no. 3, pp. 698–704, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  94. Y. Savov, N. Antonova, E. Zvetkova, Y. Gluhcheva, I. Ivanov, and I. Sainova, “Whole blood viscosity and erythrocyte hematometric indices in chronic heroin addicts,” Clinical Hemorheology and Microcirculation, vol. 35, no. 1-2, pp. 129–133, 2006. View at Google Scholar · View at Scopus
  95. L. S. Brown Jr., M. J. Hickson, D. C. Ajuluchukwu, and J. Bailey, “Medical disorders in a cohort of New York City drug abusers: Much more than HIV disease,” Journal of Addictive Diseases, vol. 12, no. 4, pp. 11–27, 1993. View at Publisher · View at Google Scholar · View at Scopus
  96. A. R. Zeiger, A. A. Patkar, R. Fitzgerald, A. Lundy, S. K. Ballas, and S. P. Weinstein, “Changes in mu opioid receptors and rheological properties of erythrocytes among opioid abusers,” Addiction Biology, vol. 7, no. 2, pp. 207–217, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. M. Senturk, O. I. Kufrevioglu, and M. Ciftci, “Effects of some analgesic anaesthetic drugs on human erythrocyte glutathione reductase: an in vitro study,” Journal of Enzyme Inhibition and Medicinal Chemistry, vol. 24, no. 2, pp. 420–424, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  98. M. Halabi-Tawil, F. Lionnet, R. Girot, C. Bachmeyer, P. P. Lévy, and S. Aractingi, “Sickle cell leg ulcers: a frequently disabling complication and a marker of severity,” British Journal of Dermatology, vol. 158, no. 2, pp. 339–344, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  99. P. Connes, Y. Lamarre, M.-D. Hardy-Dessources et al., “Decreased hematocrit-to-viscosity ratio and increased lactate dehydrogenase level in patients with sickle cell anemia and recurrent leg ulcers,” PLoS ONE, vol. 8, no. 11, Article ID e79680, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  100. A. J. Madu, A. Ubesie, K. A. Madu, B. Okwor, and C. Anigbo, “Evaluation of clinical and laboratory correlates of sickle leg ulcers,” Wound Repair and Regeneration, vol. 21, no. 6, pp. 808–812, 2013. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. C. P. Minniti, K.-M. H. Delaney, A. M. Gorbach et al., “Vasculopathy, inflammation, and blood flow in leg ulcers of patients with sickle cell anemia,” American Journal of Hematology, vol. 89, no. 1, pp. 1–6, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. A. M. M. Queiroz, J. Campos, C. Lobo, C. R. Bonini-Domingos, G. Cardoso, and S. K. Ballas, “Leg amputation for an extensive, severe and intractable sickle cell anemia ulcer in a Brazilian patient,” Hemoglobin, vol. 38, no. 2, pp. 95–98, 2014. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. S. K. Ballas, “Treatment of painful sickle cell leg ulcers with topical opioids,” Blood, vol. 99, no. 3, p. 1096, 2002. View at Publisher · View at Google Scholar · View at Scopus
  104. T. Poonawala, B. K. Levay-Young, R. P. Hebbel, and K. Gupta, “Opioids heal ischemic wounds in the rat,” Wound Repair and Regeneration, vol. 13, no. 2, pp. 165–174, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. M. Gupta, T. Poonawala, M. Farooqui, M. Ericson, and K. Gupta, “Topical fentanyl stimulates healing of ischaemic wounds in diabetic rats,” Journal of Diabetes, 2014. View at Publisher · View at Google Scholar · View at PubMed
  106. P. Farley, “Should topical opioid analgesics be regarded as effective and safe when applied to chronic cutaneous lesions?” Journal of Pharmacy and Pharmacology, vol. 63, no. 6, pp. 747–756, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. J. R. Goldsmith, J. M. Uronis, and C. Jobin, “Mu opioid signaling protects against acute murine intestinal injury in a manner involving Stat3 signaling,” The American Journal of Pathology, vol. 179, no. 2, pp. 673–683, 2011. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. M. Bigliardi-Qi, C. Gaveriaux-Ruff, K. Pfaltz et al., “Deletion of μ- and κ-opioid receptors in mice changes epidermal hypertrophy, density of peripheral nerve endings, and itch behavior,” Journal of Investigative Dermatology, vol. 127, no. 6, pp. 1479–1488, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  109. R. Sim, D. M. Cheong, K. S. Wong, B. M. K. Lee, and Q. Y. Liew, “Prospective randomized, double-blind, placebo-controlled study of pre- and postoperative administration of a COX-2-specific inhibitor as opioid-sparing analgesia in major colorectal surgery,” Colorectal Disease, vol. 9, no. 1, pp. 52–60, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. J. Moss and C. E. Rosow, “Development of peripheral opioid antagonists: new insights into opioid effects,” Mayo Clinic Proceedings, vol. 83, no. 10, pp. 1116–1130, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus